Optic Nerves Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators therapy and Others), Indication (Glaucoma, Optic Neuritis and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027
Optic Nerves Disorder Treatment Market by Treatment Type (Steroidal Therapy, Immunomodulators therapy and Others), Indication (Glaucoma, Optic Neuritis and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027
The Global Optic Nerves Disorder Treatment Market investigation report contains Types, Application & all logical and factual briefs about market Overview, CAGR, Production Volume, Sales, Revenue with the regional analysis covers North America, Europe, Asia-Pacific, South America, Middle East & Africa & The top Players like {playerNamesStr}
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The Optic Nerves are the cranial nerves which connect the retinal cells to the optic chiasm. In the retina photoreceptor cells are present which receive light and transmit it to the brain in the form of electric impulses through the optic nerves. Based on the nature and area of the injury, dysfunction or damage to the optic nerves might lead to visual loss. One can develop vision impairment in either one or both eyes. A key factor fueling the market growth is a rise in the lifestyle diseases such as diabetes, blood pressure, hypertension, etc. owing to the adoption of a inactive lifestyle unhealthy diet, dearth of physical activities, etc. which further increase the possibilities of multiple sclerosis resulting in the optic neuritis. Owing to this, there is a surge in the ratio of people requiring treatment for the disease. On the contrary, the adverse effects of using drugs for disorder treatment may limit the optic nerves disorder treatment market growth. The Optic Nerves Disorder Treatment Market is expected to rise at a rate of 4.5% CAGR by 2027.
Optic Nerves Disorder Treatment Market based on Treatment Type
Steroidal Therapy
Immunomodulators therapy
Others
Optic Nerves Disorder Treatment Market based on Indication
Glaucoma
Optic Neuritis
Others
Optic Nerves Disorder Treatment Market based on Distribution Channel
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
Optic Nerves Disorder Treatment Market based on Geography
North America
Europe
Asia Pacific
Rest of World
The market based on treatment type is further segmented as Steroidal Therapy, Immunomodulators therapy and Others. The Immunomodulators therapy segment is likely to hold the highest share in the market. The highest share of the segment is due to the rise in the research and development activities for the manufacturing of immunomodulators for optic nerve disorder treatments coupled with the surge in number of key players has resulted increase in the launch of new drugs which further boost the optic nerves disorder treatment market growth.
Based on the indication the market is categorized as Glaucoma, Optic Neuritis and Others. The glaucoma segment held the significant share in the market owing to a surge in incidence of open angle glaucoma. In addition to this, the rise in number of approvals for drugs for the treatment of open angle glaucoma is projected to boost the optic nerves disorder treatment market growth.
Then further based on distribution channel, the market is bifurcated into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The drug stores and retail pharmacies segment has the maximum share in the optic nerves disorder treatment market. Rising number of independent pharmacies and chains coupled with the availability of several rare disease medications in supermarkets and mass retailers are the reasons for segment growth.
In the regional market of optic nerves disorder treatment market, North America has acquired the major share in the market. Key factors propelling the growth of the optic nerves disorder treatment market are the substantial presence of leading pharmaceutical and biopharmaceutical companies in the North American region.
E-commerce (electronic commerce) has become a significant tool for small and large businesses worldwide, owing to the increase in preference of consumers for online shopping over conventional purchasing methods. This is ascribed to further supports for global market growth. The demand for optic nerve disorder treatment products is not only constrained to developed nations but is also being witnessed in developing nations, such as China, Brazil, and India, which boosts the growth of the global optic nerve disorder treatment market.
Prominent players operating in the market are Teva Pharmaceutical Industries Ltd, Bausch Health Companies, Inc., Santen Pharmaceutical Co. Ltd., AbbVie Inc., Novartis AG, Aerie Pharmaceuticals, Inc., Cipla Ltd, Merck & Co. Inc., mallinckrodt pharmaceuticals, and Pfizer, Inc.
As a result, there is significant scope for the optic nerve disorder treatment in the present scenario. This is due to the various factors such as advancements in the medical technology which have resulted in the development of new and more effective treatments for optic nerve disorder.
This research segments the market completely and gives the nearest evaluations of the complete market size, along with that of the sub segments among major regions.
This report gives insightful analysis of the market and gives a comprehensive understanding of the market and its commercial landscape.
Provides the information about the market strategies which are being adopted by the competitors and leading organizations.
This report provides the perception of the future outlook and prospects for market analysis and forecast.
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Treatment Type: Market Size & Analysis
5.1. Overview
5.2. Steroidal Therapy
5.3. Immunomodulators therapy
5.4. Others
6. Indication: Market Size & Analysis
6.1. Overview
6.2. Glaucoma
6.3. Optic Neuritis
6.4. Others
7. Distribution Channel: Market Size & Analysis
7.1. Overview
7.2. Hospital Pharmacies
7.3. Drug Stores and Retail Pharmacies
7.4. Online Providers
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Teva Pharmaceutical Industries Ltd
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Bausch Health Companies, Inc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Santen Pharmaceutical Co. Ltd.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. AbbVie Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Novartis AG
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Aerie Pharmaceuticals, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Cipla Ltd
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Merck & Co. Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. mallinckrodt pharmaceuticals
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Pfizer, Inc
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
Tables & Figures:
TABLE 1. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR STEROIDAL THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR IMMUNOMODULATORS THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR GLAUCOMA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OPTIC NEURITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL OPTIC NERVES DISORDER TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 19. U.S OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 22. CANADA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 32. U.K OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 44. ROE OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY TREATMENT TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD OPTIC NERVES DISORDER TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIALS
TABLE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS & SERVICES
TABLE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS
TABLE 67. BAUSCH HEALTH COMPANIES, INC.: FINANCIALS
TABLE 68. BAUSCH HEALTH COMPANIES, INC.: PRODUCTS & SERVICES
TABLE 69. BAUSCH HEALTH COMPANIES, INC.: RECENT DEVELOPMENTS
TABLE 70. SANTEN PHARMACEUTICAL CO. LTD.: FINANCIALS
TABLE 71. SANTEN PHARMACEUTICAL CO. LTD.: PRODUCTS & SERVICES
TABLE 72. SANTEN PHARMACEUTICAL CO. LTD.: RECENT DEVELOPMENTS
TABLE 73. ABBVIE INC.: FINANCIALS
TABLE 74. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 75. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 76. NOVARTIS AG: FINANCIALS
TABLE 77. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 78. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 79. AERIE PHARMACEUTICALS, INC.: FINANCIALS
TABLE 80. AERIE PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 81. AERIE PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 82. CIPLA LTD: FINANCIALS
TABLE 83. CIPLA LTD: PRODUCTS & SERVICES
TABLE 84. CIPLA LTD: RECENT DEVELOPMENTS
TABLE 85. MERCK & CO. INC.: FINANCIALS
TABLE 86. MERCK & CO. INC.: PRODUCTS & SERVICES
TABLE 87. MERCK & CO. INC.: RECENT DEVELOPMENTS
TABLE 88. MALLINCKRODT PHARMACEUTICALS: FINANCIALS
TABLE 89. MALLINCKRODT PHARMACEUTICALS: PRODUCTS & SERVICES
TABLE 90. MALLINCKRODT PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 91. PFIZER, INC.: FINANCIALS
TABLE 92. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 93. PFIZER, INC.: RECENT DEVELOPMENTS
Research Methodology:
Optic Nerves Disorder Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|